MX2017005158A - Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). - Google Patents
Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk).Info
- Publication number
- MX2017005158A MX2017005158A MX2017005158A MX2017005158A MX2017005158A MX 2017005158 A MX2017005158 A MX 2017005158A MX 2017005158 A MX2017005158 A MX 2017005158A MX 2017005158 A MX2017005158 A MX 2017005158A MX 2017005158 A MX2017005158 A MX 2017005158A
- Authority
- MX
- Mexico
- Prior art keywords
- substituted
- unsubstituted
- alkenyl
- hydrogen atom
- alkynyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
Abstract
La presente invención se refiere a un compuesto representado por la fórmula: (ver Fórmula) o su sal farmacéuticamente aceptable, en donde L es NR2R3, SR7, SO2R8, alquilo sustituido o no sustituido, o alquenilo sustituido o no sustituido; R2 es hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, o similares; R3 es hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, o similares; R7 es hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, o similares; R8 es hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, o similares, siempre que R8 is not unsubstituted metil o trifluorometilo; Y es alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, arilo sustituido o no sustituido, o similares, siempre que Y no sea metilo no sustituido o etilo no sustituido; Z es -CR6=, o -N=; R1 es hidrógeno, o alquilo sustituido o no sustituido; R4, R5 y R6 son cada uno independientemente hidrógeno, halógeno, hidroxi, ciano, nitro, carboxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, o similares.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014218860 | 2014-10-28 | ||
JP2015085522 | 2015-04-20 | ||
PCT/JP2015/080162 WO2016068099A1 (ja) | 2014-10-28 | 2015-10-27 | Ampk活性化作用を有する複素環誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005158A true MX2017005158A (es) | 2017-07-27 |
Family
ID=55857436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005158A MX2017005158A (es) | 2014-10-28 | 2015-10-27 | Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). |
Country Status (10)
Country | Link |
---|---|
US (1) | US10123994B2 (es) |
EP (1) | EP3214076A4 (es) |
JP (1) | JPWO2016068099A1 (es) |
KR (1) | KR20170077131A (es) |
CN (1) | CN107108521A (es) |
AU (1) | AU2015338042A1 (es) |
CA (1) | CA2965781A1 (es) |
MX (1) | MX2017005158A (es) |
RU (1) | RU2700703C2 (es) |
WO (1) | WO2016068099A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10478425B2 (en) | 2016-02-26 | 2019-11-19 | Shionogi & Co., Ltd. | 5-phenylazaindole derivative having AMPK-activating activity |
JPWO2017188288A1 (ja) * | 2016-04-26 | 2019-02-28 | 塩野義製薬株式会社 | Ampk活性化作用を有する5−置換アザベンズイミダゾール誘導体 |
US10406140B2 (en) | 2016-05-20 | 2019-09-10 | Shionogi & Co., Ltd. | 5-substituted benzimidazole and 5-substituted azabenzimidazole derivative both having AMPK activation effect |
CN106083707B (zh) * | 2016-06-01 | 2018-10-26 | 温州大学 | 一种非对称杂芳基硫醚的合成方法 |
EP3781572A1 (en) * | 2018-04-20 | 2021-02-24 | Virginia Tech Intellectual Properties, Inc. | Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers |
WO2021226261A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8417194D0 (en) * | 1984-07-05 | 1984-08-08 | Boots Co Plc | Therapeutic agents |
JPH05339224A (ja) | 1992-06-10 | 1993-12-21 | Tokuyama Soda Co Ltd | シアノケトン誘導体の製造方法 |
JP5042626B2 (ja) * | 2003-09-22 | 2012-10-03 | エス*バイオ プライベート リミティッド | ベンズイミダゾール誘導体:製造及び医薬適用 |
JPWO2005082905A1 (ja) | 2004-02-26 | 2007-08-02 | 協和醗酵工業株式会社 | 二環性複素環化合物 |
EP1789381A4 (en) | 2004-07-12 | 2009-11-11 | Merck & Co Inc | Histone deacetylase INHIBITORS |
US7429608B2 (en) * | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
CN101479249B (zh) * | 2006-06-29 | 2012-10-10 | 霍夫曼-拉罗奇有限公司 | 苯并咪唑衍生物、其制备方法、它们作为fxr激动剂的用途及含有它们的药物制剂 |
JP4866901B2 (ja) | 2007-02-07 | 2012-02-01 | 協和発酵キリン株式会社 | 3環系化合物 |
EA019309B1 (ru) | 2008-02-04 | 2014-02-28 | Меркьюри Терапьютикс, Инк. | Модуляторы ampk (амф-активируемой протеинкиназы) |
MX2011003239A (es) | 2008-09-26 | 2011-04-28 | Merck Sharp & Dohme | Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos. |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2352374B1 (en) | 2008-10-29 | 2014-09-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
PT2389375E (pt) * | 2009-01-23 | 2015-09-17 | Euro Celtique Sa | Derivados de ácido hidroxâmico |
US8492374B2 (en) | 2009-04-29 | 2013-07-23 | Industrial Technology Research Institute | Azaazulene compounds |
US8545681B2 (en) * | 2009-12-23 | 2013-10-01 | General Electric Company | Waste heat driven desalination process |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
RU2635662C2 (ru) * | 2010-09-10 | 2017-11-15 | Сионоги Энд Ко., Лтд. | Конденсированное с гетерокольцом имидазольное производное, обладающее активирующим амрк действием |
WO2012040499A2 (en) * | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
JP2012167027A (ja) | 2011-02-10 | 2012-09-06 | Shionogi & Co Ltd | Npyy5受容体拮抗作用を有する縮合ヘテロ環誘導体 |
EA025380B1 (ru) | 2011-02-25 | 2016-12-30 | Мерк Шарп Энд Домэ Корп. | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов |
WO2012147765A1 (ja) | 2011-04-27 | 2012-11-01 | 塩野義製薬株式会社 | Npy y5受容体拮抗作用を有するベンズイミダゾール誘導体 |
EP3495366A1 (en) * | 2011-07-15 | 2019-06-12 | Shionogi & Co., Ltd | Azabenzimidazole derivative having ampk-activating activity |
US9382243B2 (en) | 2012-08-22 | 2016-07-05 | Merck Sharp & Dohme Corp. | Azabenzimidazole tetrahydropyran derivatives |
US9868733B2 (en) | 2012-08-22 | 2018-01-16 | Merck Sharp & Dohme Corp. | Azabenzimidazole tetrahydrofuran derivatives |
CN104718004A (zh) | 2012-08-22 | 2015-06-17 | 默沙东公司 | 新的氮杂苯并咪唑六氢呋喃并[3,2-b]呋喃衍生物 |
WO2014031441A1 (en) | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel benzimidazole tetrahydrofuran derivatives |
ES2755087T3 (es) | 2012-08-22 | 2020-04-21 | Merck Sharp & Dohme | Derivados de benzimidazol hexahidrofuro[3,2-b]furano útiles como activadores de proteína cinasa activada por AMP |
US9527839B2 (en) | 2012-08-22 | 2016-12-27 | Merck Sharp & Dohme Corp. | Benzimidazole tetrahydropyran derivatives |
WO2014069426A1 (ja) | 2012-10-31 | 2014-05-08 | 塩野義製薬株式会社 | Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体 |
US9890119B2 (en) | 2013-02-27 | 2018-02-13 | Shionogi & Co., Ltd. | Indole and azaindole derivative having AMPK-activating activity |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
JP6372891B2 (ja) | 2013-04-24 | 2018-08-15 | 塩野義製薬株式会社 | Ampk活性化作用を有する5−オキシベンズイミダゾールおよび5−オキシアザベンズイミダゾール誘導体 |
KR20160018686A (ko) | 2013-06-10 | 2016-02-17 | 아스테라스 세이야쿠 가부시키가이샤 | 이환식 함질소 방향족 헤테로고리 아미드 화합물 |
DK3022210T3 (en) | 2013-07-17 | 2018-06-06 | Boehringer Ingelheim Int | NEW AZABENZIMIDAZOLD DERIVATIVES. |
EP3063148B1 (en) | 2013-10-31 | 2020-04-29 | Boehringer Ingelheim International GmbH | Azabenzimidazole derivatives |
EP3180338B1 (en) | 2014-08-11 | 2018-05-09 | Boehringer Ingelheim International GmbH | Azabenzimidazole derivatives as amp protein kinase agonistes |
RU2017107543A (ru) | 2014-08-27 | 2018-10-02 | Шионоги Энд Ко., Лтд. | Производное азаиндола с аmpk-активирующим действием |
EP3245212B1 (en) | 2015-01-16 | 2019-03-13 | Boehringer Ingelheim International GmbH | New azabenzimidazole derivatives |
JP6612880B2 (ja) | 2015-01-16 | 2019-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Amp活性化タンパク質キナーゼのアゴニストとしての新規アザベンゾイミダゾール誘導体 |
-
2015
- 2015-10-27 KR KR1020177011169A patent/KR20170077131A/ko unknown
- 2015-10-27 AU AU2015338042A patent/AU2015338042A1/en not_active Abandoned
- 2015-10-27 MX MX2017005158A patent/MX2017005158A/es unknown
- 2015-10-27 WO PCT/JP2015/080162 patent/WO2016068099A1/ja active Application Filing
- 2015-10-27 CA CA2965781A patent/CA2965781A1/en not_active Abandoned
- 2015-10-27 RU RU2017118335A patent/RU2700703C2/ru not_active IP Right Cessation
- 2015-10-27 CN CN201580058988.XA patent/CN107108521A/zh active Pending
- 2015-10-27 EP EP15855481.6A patent/EP3214076A4/en not_active Withdrawn
- 2015-10-27 US US15/522,504 patent/US10123994B2/en not_active Expired - Fee Related
- 2015-10-27 JP JP2016556567A patent/JPWO2016068099A1/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3214076A4 (en) | 2018-07-25 |
KR20170077131A (ko) | 2017-07-05 |
EP3214076A1 (en) | 2017-09-06 |
AU2015338042A1 (en) | 2017-04-27 |
US10123994B2 (en) | 2018-11-13 |
WO2016068099A1 (ja) | 2016-05-06 |
US20170333398A1 (en) | 2017-11-23 |
RU2017118335A (ru) | 2018-11-29 |
CA2965781A1 (en) | 2016-05-06 |
CN107108521A (zh) | 2017-08-29 |
RU2017118335A3 (es) | 2018-11-29 |
RU2700703C2 (ru) | 2019-09-19 |
JPWO2016068099A1 (ja) | 2017-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017005158A (es) | Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). | |
PH12018502136A1 (en) | Heterocyclic amides useful as protein modulators | |
PH12018500341A1 (en) | Heterocyclic amides as kinase inhibitors | |
MX2016011992A (es) | Derivados de piperidina-diona. | |
PH12016501813A1 (en) | 1,3-benzodioxole derivative | |
PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
IN2014MN01897A (es) | ||
PH12015500209A1 (en) | Partially saturated nitrogen-containing heterocyclic compound | |
MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
MX2016009794A (es) | Derivado de sulfonamida heterociclico y medicina que comprende el mismo. | |
GEP20186878B (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders | |
PH12017500095A1 (en) | Imidazopyridazine compounds | |
MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
MX367554B (es) | Derivados heterocíclicos y sus usos. | |
MX2016012451A (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina. | |
GEP20186934B (en) | Quinolizinone derivatives as pi3k inhibitors | |
EA201691566A1 (ru) | Применение производных пиридазина для предупреждения или лечения атаксического синдрома | |
MX2015007309A (es) | Derivado de hidantoina. | |
PH12016501645A1 (en) | Aminopyrazolone derivative | |
EA201892424A1 (ru) | Гетероциклические амиды, пригодные в качестве модуляторов белков | |
MX358151B (es) | Derivado de sitaxentan. | |
UA99044U (ru) | (4-амино-3-(децилтио)-1,2,4-триазол-5-ил)(фенил)метанола, проявляющей диуретическую активность |